𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Treatment patterns in low-grade non-Hodgkin's lymphomas: A single institution study

✍ Scribed by Liesveld, Jane L. ;Raubertas, Richard F. ;Bennett, John M.


Publisher
John Wiley and Sons
Year
1991
Tongue
English
Weight
599 KB
Volume
19
Category
Article
ISSN
0098-1532

No coin nor oath required. For personal study only.

✦ Synopsis


Ninety-two cases of low-grade non-Hodgkin's lymphoma were examined retrospectively to assess to what extent treatment deferral is practiced at a single university hospital with a local referral base. Clinical characteristics of this patient group were also analyzed; 70% of these cases were of nodular lymphocytic, poorly differentiated (NLPD) histology, and 74% were stage III or IV. Twenty-two cases were not treated initially. Nine eventually required treatment at a median of 16 months. Survival did not differ based on whether treatment was initially deferred. Nodal progression was the most common reason for beginning treatment after initial deferral, and most cases of advanced stage disease required treatment because of nodal involvement or B-type symptoms at diagnosis. Presence of intra-abdominal adenopathy often prompted initial treatment even in asymptomatic cases. In this series, as compared to previously reported series of treatment-deferred cases, more patients were judged to require treatment at disease outset, and the median time to treatment in those in whom treatment was initially deferred but then instituted was shorter. Despite this, for the entire population, 69% of total follow-up time was spent off therapy.


πŸ“œ SIMILAR VOLUMES


Treatment of low-grade non-Hodgkin's lym
✍ Dr. E. Lepage; C. Sebban; C. Gisselbrecht; B. Coiffier; J. L. Harousseau; P. A. πŸ“‚ Article πŸ“… 1990 πŸ› John Wiley and Sons 🌐 English βš– 501 KB

From 1981 to 1984 a randomized clinical trial was conducted to evaluate the role of doxorubicin in low grade malignancy non-Hodgkin's lymphoma (NHL). One hundred and thirteen patients were treated by an induction regimen including cyclophosphamide 400 mg/m2 day I and 8, vincristine 1.4 mg/m2 day 1 a

Ifosfamide in the treatment of high-grad
✍ Ian Magrath; Melissa Adde; John Sandlund; Vinay Jain πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 491 KB πŸ‘ 1 views

We report the results of two phase I1 trials of ifosfamide in very high risk patients with either partially responsive or recurrent non-Hodgkin's lymphomas. In the first study, in which patients were extremely heavily pretreated (50 per cent had received a very intensive salvage regimen containing v

CD45 expression in low-grade B-cell non-
✍ Giovanni Carulli; Elisa Cannizzo; Alessandra Zucca; Gabriele Buda; Enrico Orciuo πŸ“‚ Article πŸ“… 2008 πŸ› Elsevier Science 🌐 English βš– 223 KB

CD45 is a glycoprotein expressed in all lymphohemopoietic cells. Its expression increases during B-lymphocyte ontogeny. Few data are available about CD45 expression in the various types of low-grade B-cell non-Hodgkin's lymphomas (NHL). Low levels of CD45 have been reported in pathologic lymphocytes